Upregulation of MICA on high-grade invasive operable breast carcinoma
- PMID: 17948965
- PMCID: PMC2935745
Upregulation of MICA on high-grade invasive operable breast carcinoma
Abstract
The MHC class I chain-related gene A (MICA) is frequently expressed on the surface of intestinal epithelium and by many epithelial tumours. MICA is a stress-induced antigen which was identified as an activator of natural killer cells via interaction with the NKG2D receptor. We have raised a rabbit polyclonal antibody against a synthetic peptide that recognises denatured MICA on both Western blots and in formalin-fixed paraffin-embedded sections. In the present study this antibody was used to undertake a definitive study of 530 breast cancer cases with mean follow up of 7 years to determine the prognostic significance of MICA expression. To detect any association between MICA expression and NK infiltration, whole sections of 50 tumours were also analysed for CD56 staining. Univariate analysis showed significant relationships between MICA expression and histological grade (P = 0.006), lymph node stage (P = 0.013), Nottingham Prognostic Index (NPI, P = 0.002), the presence of vascular invasion (P = 0.045) and tumour type (P = 0.023). Upregulation of MICA was more often found in histological grade 3, poor prognosis (NPI >5.4) tumours. Association of high MICA expression with NK cell infiltration was not demonstrated, as very few NK cells were present in whole breast sections. Our results suggest that induced expression of MICA may be an indicator of poor prognosis in breast carcinoma and is indicative of a tumour environment that has undergone stresses such as apoptosis, necrosis, or hypoxia.
Figures









Similar articles
-
CD56+ immune cell infiltration and MICA are decreased in breast lobules with fibrocystic changes.Breast Cancer Res Treat. 2018 Feb;167(3):649-658. doi: 10.1007/s10549-017-4558-0. Epub 2017 Nov 1. Breast Cancer Res Treat. 2018. PMID: 29090365 Free PMC article.
-
Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast.Oncology. 2005;68(4-6):398-404. doi: 10.1159/000086981. Epub 2005 Jul 12. Oncology. 2005. PMID: 16020969
-
Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients.Pathol Oncol Res. 2018 Jul;24(3):631-640. doi: 10.1007/s12253-017-0288-1. Epub 2017 Aug 14. Pathol Oncol Res. 2018. PMID: 28808873
-
Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.Int J Cancer. 2013 Oct 1;133(7):1557-66. doi: 10.1002/ijc.28174. Epub 2013 Apr 18. Int J Cancer. 2013. PMID: 23526433
-
Granulin-epithelin precursor renders hepatocellular carcinoma cells resistant to natural killer cytotoxicity.Cancer Immunol Res. 2014 Dec;2(12):1209-19. doi: 10.1158/2326-6066.CIR-14-0096. Epub 2014 Oct 14. Cancer Immunol Res. 2014. PMID: 25315249
Cited by
-
Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy.J Hematol Oncol. 2020 Jun 9;13(1):74. doi: 10.1186/s13045-020-00896-0. J Hematol Oncol. 2020. PMID: 32517713 Free PMC article.
-
The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer.Breast Care (Basel). 2018 Mar;13(1):16-21. doi: 10.1159/000486585. Epub 2018 Feb 2. Breast Care (Basel). 2018. PMID: 29950962 Free PMC article. Review.
-
Prognostic value of soluble MICA levels in the serum of patients with advanced hepatocellular carcinoma.Chin J Cancer. 2013 Mar;32(3):141-8. doi: 10.5732/cjc.012.10025. Epub 2012 Jun 14. Chin J Cancer. 2013. PMID: 22704489 Free PMC article.
-
Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein.J Immunother Cancer. 2020 Jun;8(1):e000233. doi: 10.1136/jitc-2019-000233. Epub 2020 Jun 8. J Immunother Cancer. 2020. PMID: 32518090 Free PMC article.
-
The immune system in cancer metastasis: friend or foe?J Immunother Cancer. 2017 Oct 17;5(1):79. doi: 10.1186/s40425-017-0283-9. J Immunother Cancer. 2017. PMID: 29037250 Free PMC article. Review.
References
-
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. - PubMed
-
- Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329–360. - PubMed
-
- Madjd Z, Pinder SE, Paish C, Ellis IO, Carmichael J, Durrant LG. Loss of CD59 expression in breast tumours correlates with poor survival. J Pathol. 2003;200:633–639. - PubMed
-
- Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today. 1997;18:89–95. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials